Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C1626
http://purl.obolibrary.org/obo/NCIT_C1626
Preferred Name

Etalocib
Definitions
A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.
prefLabel
Etalocib
label
Etalocib
PDQ_Closed_Trial_Search_ID
38111
code
C1626
prefixIRI
NCIT:C1626
in_subset
Preferred_Name
Etalocib
FDA_UNII_Code
THY6RIW44R
Contributing_Source
FDA
Chemical_Formula
C33H33FO6
Maps_To
Etalocib
CAS_Registry
161172-51-6
NCI_Drug_Dictionary_ID
38111
Legacy Concept Name
LY293111
type
ALT_DEFINITION
A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called leukotriene B4 receptor antagonists.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
38111
Semantic_Type
Organic Chemical
Pharmacologic Substance
UMLS_CUI
C0298619
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display